The Beachbody Company, Inc. (BODI), also known as BODi, operates a fitness and nutrition business across the United States, Canada, the United Kingdom, and France. Its model blends a digital subscription platform with nutrition supplements and connected-fitness products. The streaming service Beachbody on Demand Interactive features programs such as P90X, Insanity, 21 Day Fix, and LIIFT4, while its nutrition offerings include Shakeology and Beachbody Performance supplements.
Investors track BODI closely as the company shifts from its legacy multi-level marketing approach toward a nutrition-led, multi-channel strategy that includes direct-to-consumer, Amazon, and retail channels. The transition aims to expand its market reach, though it has coincided with ongoing revenue declines. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, BODI shares have fallen roughly 25%, moving from a closing level near $4.57 to about $3.43. Much of the drop came in one session after the third-quarter earnings release, when the stock fell from $4.51 to close near $3.34.
The quarterly picture looks even weaker. Over the trailing three months, the stock has declined approximately 36% and now trades near the bottom of its 52-week range of roughly $3.16 to $16.87. The broader trend reflects persistent revenue contraction, cautious forward guidance, and a market reassessment of the turnaround timeline.
The primary catalyst was the third-quarter 2026 earnings report released on November 10, 2026. Revenue of $45.19 million marked a 24.5% year-over-year decline and missed consensus expectations of roughly $52.6 million. While GAAP EPS of $0.38 and adjusted EPS of $0.09 beat estimates, and adjusted EBITDA stayed positive for a twelfth straight quarter at about $6.4 million, the market focused on the weak top line and soft outlook.
Management guided fourth-quarter revenue to $38 million to $42 million, below the consensus of approximately $47 million. The company also noted an early October restructuring that reduced its cost base by more than $30 million. In response, several analysts lowered price targets: Roth Capital cut its target to $5 from $9 (Neutral), Craig-Hallum to $8 from $18 (Buy), and Canaccord to $12 from $16 (Buy). From what I see, the combination of the revenue miss, conservative guidance, and reduced targets triggered the sharp single-day move.
The quarterly decline fits a longer narrative where legacy businesses continue to shrink faster than newer nutrition and retail initiatives can compensate. While BODI has posted several consecutive quarters of positive net income and adjusted EBITDA through cost discipline, revenue has contracted as subscriber attrition persists and new customer acquisition stays uneven.
The pivot toward a nutrition-led, multi-channel model has included new launches such as P90X ready-to-drink energy cans and the INSANITY-branded Liquid Shock energy drink, along with planned programs like INSANITY: UNHINGED and the BODi 365 platform for 2027. These efforts have yet to generate enough traction to reverse the top-line trend, keeping sentiment cautious.
Looking ahead, attention will center on fourth-quarter revenue performance within the guided $38 million to $42 million range, especially around Black Friday and Cyber Monday. Progress on new customer acquisition in nutrition and across Amazon and retail channels will indicate whether the multi-channel strategy is gaining ground. Other areas include the rollout of new INSANITY and P90X products, the shift of supplement manufacturing to a turnkey model, and any further cost actions. Macro conditions, competitive pressures, and analyst revisions will also influence sentiment, with revenue stabilization remaining the central question for the stock.
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check patterns and signals on names like this. The platform helps surface relevant trading ideas across thousands of tickers and has become a regular part of how I evaluate opportunities without hours of manual work. It provides an additional layer of perspective that complements traditional fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where BODI advanced for three days, in 197 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
BODI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BODI as a result. In 88 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BODI turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BODI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BODI entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 24 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.832) is normal, around the industry mean (0.974). P/E Ratio (2.388) is within average values for comparable stocks, (-39.046). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (17.274). Dividend Yield (0.000) settles around the average of (0.979) among similar stocks. P/S Ratio (0.167) is also within normal values, averaging (71.888).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. BODI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BODI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InternetSoftwareServices